Acute myeloid leukemia (AML) is classified as a hematologic malignancy characterized by the proliferation of immature blood cells within the bone marrow (BM), resulting in an aberrant and unregulated cellular growth. The primary therapeutic modalities for AML include chemotherapy and hematopoietic stem cell transplantation. However, it is important to note that these treatments are accompanied by important adverse effects and mortality rates. Therefore, the need for more effective treatment options seems necessary, and dendritic cell (DC) vaccine therapy can be one of these options. In this study, we aim to investigate the effectiveness of DC vaccination therapy for the management of AML. PubMed, Scopus, ProQuest, Web of Science, and Google Scholar databases were searched for this systematic review. The articles were evaluated based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, the articles related to the topic of this review were obtained in full text. The complete remission and partial remission, survival, correlative immune assays, and health-related metrics were used to evaluate this cellular immunotherapy effectiveness. The quality of the studies was assessed independently using the Cochrane risk-of-bias tools. The compiled data were input into a standard Excel spreadsheet. Each domain was evaluated as having either a “low risk,” “high risk,” or “unclear risk” of bias. Among the 3986 studies that were determined, a total of 11 correlated trials were selected for inclusion in this systematic review. DC vaccine therapy was effective in inducing complete and partial remission, and stabilization of the disease. Additionally, it was discovered that the treatment strengthened the immune system as seen by increased levels of CD4 and CD8 T cells, Th1 cytokines, WT1-specific T cells, and activated NK cells. We conducted a systematic review that supports the use of DC vaccine therapy as an effective treatment for AML. The therapy demonstrated potentials in achieving remission, enhancing the immune system function, and increasing overall survival. However, more studies are required to improve the methods of preparing and delivering the DC vaccine, and to confirm its long-term safety and effectiveness.

中文翻译：

---

治疗急性髓系白血病的树突状细胞疫苗接种策略：系统评价

急性髓系白血病 (AML) 被归类为一种血液恶性肿瘤，其特征是骨髓 (BM) 内未成熟血细胞的增殖，导致细胞生长异常且不受调节。 AML的主要治疗方式包括化疗和造血干细胞移植。然而，值得注意的是，这些治疗方法伴随着重要的副作用和死亡率。因此，似乎需要更有效的治疗方案，而树突状细胞（DC）疫苗疗法可能就是其中之一。在这项研究中，我们的目的是调查 DC 疫苗接种治疗治疗 AML 的有效性。为了这篇系统评价，我们检索了 PubMed、Scopus、ProQuest、Web of Science 和 Google Scholar 数据库。根据本研究的纳入标准对文章进行评估，并初步在标题或摘要方面进行比较。最后获得与本综述主题相关的文章全文。使用完全缓解和部分缓解、生存、相关免疫测定和健康相关指标来评估这种细胞免疫疗法的有效性。使用 Cochrane 偏倚风险工具对研究质量进行独立评估。编译后的数据被输入到标准 Excel 电子表格中。每个领域都被评估为具有“低风险”、“高风险”或“不清楚风险”的偏见。在确定的3986项研究中，总共选择了11项相关试验纳入本次系统评价。 DC 疫苗疗法可有效诱导完全和部分缓解以及疾病稳定。此外，还发现该治疗增强了免疫系统，表现为 CD4 和 CD8 T 细胞、Th1 细胞因子、WT1 特异性 T 细胞和活化 NK 细胞水平的增加。我们进行了系统评价，支持使用 DC 疫苗疗法作为 AML 的有效治疗方法。该疗法显示出实现缓解、增强免疫系统功能和提高总体生存率的潜力。然而，还需要更多的研究来改进 DC 疫苗的制备和递送方法，并确认其长期安全性和有效性。